Conduit Pharmaceuticals
About: Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Employees: 7
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
250% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 4
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
24% more funds holding
Funds holding: 29 [Q2] → 36 (+7) [Q3]
0.18% more ownership
Funds ownership: 4.04% [Q2] → 4.22% (+0.18%) [Q3]
85% less capital invested
Capital invested by funds: $3.18M [Q2] → $480K (-$2.7M) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for CDT.
